HealthcareServices

Global Chronic Spontaneous Urticaria Market Forecast 2026–2035: Long-Term Growth Insights

February 23, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the chronic spontaneous urticaria market from 2026–2035 with trusted insights from The Business Research Company

What size range is anticipated for the Chronic Spontaneous Urticaria Market from 2026 to 2030?

The chronic spontaneous urticaria market size has demonstrated robust growth in recent years. It is projected to increase from $2.23 billion in 2025 to $2.41 billion in 2026, at a compound annual growth rate (CAGR) of 8.4%. This historical expansion can be attributed to a rising prevalence of chronic skin allergies, the broader availability of second-generation antihistamines, advancements in diagnostic practices, an uptick in dermatology clinic visits, and greater patient awareness regarding urticaria conditions.

The market for chronic spontaneous urticaria is anticipated to experience substantial growth over the coming years. Projections indicate it will reach a value of $3.21 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.4%. This projected expansion during the forecast period is fueled by factors such as the expanding development pipeline for biologic drugs, heightened investment in autoimmune dermatology research, wider application of targeted monoclonal antibodies, an increasing emphasis on achieving symptom-free disease management, and the greater uptake of long-term maintenance treatments. Key trends expected during this period involve the growing acceptance of biologic therapies for csu, an increase in the utilization of advanced antihistamine protocols, a deepened focus on the underlying mechanisms of autoimmune diseases, the broadening of personalized treatment approaches, and improved monitoring for sustained disease control.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16651&type=smp

What Drivers Are Affecting Demand In The Chronic Spontaneous Urticaria Market?

A rise in alcohol intake is projected to fuel the expansion of the chronic spontaneous urticaria market in the coming period. This elevated alcohol usage stems from multiple elements, including societal customs, pressure, promotional activities, cost-effectiveness, and accessibility. For certain people, ingesting alcohol might worsen the indicators of chronic spontaneous urticaria, resulting in more pronounced hives and puffiness. For example, in 2025, as per the Priory Group, a UK-based provider of mental health, addiction, and specialist education services, a 2023 survey revealed that 25% of UK individuals aged 18–24 now completely abstain from alcohol, showcasing a remarkable trend towards sobriety within the younger demographic. Consequently, the growing intake of alcohol is stimulating the expansion of the chronic spontaneous urticaria market.

Which Segments Are Gaining Traction In The Chronic Spontaneous Urticaria Market?

The chronic spontaneous urticaria market covered in this report is segmented –

1) By Treatment: Medication, Phototherapy, Other Treatments

2) By Route Of Administration: Oral, Topical, Parenteral, Other Routes Of Administrations

3) By Diagnosis: Physical Examination, Blood Test, Allergy Test, Other Diagnosis

4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Medication: Antihistamines, Leukotriene Receptor Antagonists, Monoclonal Antibodies, Immunosuppressants, Corticosteroids

2) By Phototherapy: UVB Phototherapy, UVA Phototherapy, Narrowband UVB Therapy

3) By Other Treatments: Alternative Therapies, Dietary Modifications, Psychotherapy

Which Innovation Trends Are Advancing Developments Within The Chronic Spontaneous Urticaria Market?

Leading companies within the chronic spontaneous urticaria market are actively engaged in developing advanced next-generation Briquilimab (JSP191) to boost treatment effectiveness and reduce dosing frequency. This next-generation Briquilimab (JSP191) is a monoclonal antibody specifically designed to target and deplete certain immune cells, particularly those expressing CD47, which are implicated in conditions like chronic spontaneous urticaria. For example, in November 2023, Jasper Therapeutics Inc., a US-based clinical-stage biotechnology company, announced it had administered the initial dose to a patient in a Phase 1b/2a clinical study involving Briquilimab for chronic spontaneous urticaria (CSU). This accomplishment marks a vital step in evaluating the safety and effectiveness of Briquilimab, which is a next-generation monoclonal antibody targeting CD47, for treating this recurring issue of hives and itching. The study’s main goal is to ascertain how effectively Briquilimab can ease symptoms and improve the quality of life for patients affected by CSU.

Who Are The Major Companies Operating In The Chronic Spontaneous Urticaria Market?

Major companies operating in the chronic spontaneous urticaria market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi SA, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Genentech Inc., Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals plc, Celltrion Inc., Allakos Inc., United BioPharma Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/chronic-spontaneous-urticaria-global-market-report

Which Global Regions Are Shaping The Competitive Landscape Of The Chronic Spontaneous Urticaria Market?

North America was the largest region in the chronic spontaneous urticaria market in 2025. The regions covered in the chronic spontaneous urticaria market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Chronic Spontaneous Urticaria Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16651&type=smp

Browse Through More Reports Similar to the Global Chronic Spontaneous Urticaria Market 2026, By The Business Research Company

Atopic Dermatitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/atopic-dermatitis-global-market-report

Allergic Rhinitis Market Report 2026

https://www.thebusinessresearchcompany.com/report/allergic-rhinitis-global-market-report

Dermatitis Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795